101,800 Shares in Haemonetics Corporation $HAE Bought by Kestrel Investment Management Corp

Kestrel Investment Management Corp acquired a new stake in Haemonetics Corporation (NYSE:HAE) during the 3rd quarter, Holdings Channel reports. The firm acquired 101,800 shares of the medical instruments supplier’s stock, valued at approximately $4,961,000. Haemonetics comprises approximately 2.8% of Kestrel Investment Management Corp’s portfolio, making the stock its 14th largest position.

Other institutional investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the period. Versant Capital Management Inc increased its holdings in Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares during the last quarter. Byrne Asset Management LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at about $42,000. Hantz Financial Services Inc. grew its position in shares of Haemonetics by 792.1% during the third quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 998 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Haemonetics in the second quarter worth about $64,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

Shares of HAE stock opened at $63.28 on Monday. The company has a market capitalization of $2.94 billion, a P/E ratio of 17.43, a P/E/G ratio of 1.32 and a beta of 0.28. The company’s 50-day simple moving average is $70.13 and its two-hundred day simple moving average is $64.19. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. During the same quarter last year, the firm posted $1.19 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

HAE has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Robert W. Baird set a $81.00 price target on shares of Haemonetics in a research report on Friday, February 6th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. JPMorgan Chase & Co. boosted their target price on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a report on Friday, December 12th. Finally, Barrington Research set a $94.00 target price on shares of Haemonetics in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $84.44.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.